Skip to content

Exercise Effects in Multiple Sclerosis

Evaluating Task-Oriented Exercise Effects on Walking Function and the Central Nervous System in People With Multiple Sclerosis

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05496881
Enrollment
69
Registered
2022-08-11
Start date
2022-06-15
Completion date
2025-04-30
Last updated
2024-02-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Sclerosis, Multiple Sclerosis, Chronic Progressive, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive

Keywords

Progressive Multiple Sclerosis, Relapsing-Remitting Multiple Sclerosis, Central Nervous System, Motor Learning, Transcranial Magnetic Stimulation, Mobility Limitation

Brief summary

A growing body of work suggests that regular exercise can support symptom management and improve physical function for people living with multiple sclerosis (MS). Although exercise is known to be beneficial for managing many symptoms related to MS, its effects on the central nervous system, and whether these effects change with different types of exercise, are not well understood. Here, the investigators have designed a clinical trial that compares the effects of distinct exercise protocols on aspects of physical function, physical fitness, and central nervous system function. This research will be the first to compare the effects of different types of exercise on central nervous system changes in people with MS.

Detailed description

A total of 69 participants with multiple sclerosis (MS) and moderate motor disability in the province of Saskatchewan, Canada will be randomly assigned to receive one of three distinct exercise programs. All exercise programs will be delivered three times per week in 60-minute group sessions over the course of 12 weeks under the supervision of Clinical Exercise Physiologists. Exercise programming will include activities focused on mobility, fitness, and flexibility. Assessments of physical function, physical fitness, and central nervous system function will be conducted immediately before, after, and six weeks following completion of the exercise programs.

Interventions

OTHERExercise Group 1

Prescribed exercises will focus on mobility and balance.

OTHERExercise Group 2

Prescribed exercises will focus on physical fitness.

OTHERExercise Group 3

Prescribed exercises will focus on flexibility, range of motion, and muscle tone.

Sponsors

First Steps Wellness Centre
CollaboratorUNKNOWN
Saskatchewan Health Research Foundation
CollaboratorOTHER
University of Saskatchewan
CollaboratorOTHER
University of Regina
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Masking description

Participants will not be informed of the different study arms. Interventions will be scheduled to avoid contact between study arms. Participants will be asked to not describe their activities to those outside of their exercise group. Although it will not be possible to blind program instructors from the intervention that they deliver, instructors will not be aware of the expected results. Assessors and data analysts will be fully blinded to study arm allocation.

Intervention model description

All interventions will involve 60-minute sessions delivered three times per week for 12 weeks. All interventions will involve the whole body but differ in content.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* diagnosis of progressive MS by a neurologist * physician clearance for exercise * a Patient-Determined Disease Steps (PDSS) score between 3 and 7 (i.e., moderate motor disability) * a Timed 25-Foot Walk (T25-FW) test time \> 6.0 s.

Exclusion criteria

* a baseline score \>24 on the Godin-Shephard Leisure Time Physical Activity Questionnaire (i.e., high physical activity levels) * absolute contraindications to TMS (e.g. history of seizure) * a history of any neurological conditions other than MS * relapse in the past three months (self-reported, neurologist confirmed) * psychiatric diagnosis * substance abuse

Design outcomes

Primary

MeasureTime frameDescription
Timed 25-Foot Walk Test6 weeks post interventionThe Timed 25-Foot Walk Test provides an assessment of mobility and lower-extremity function through a measurement of fast walking speed. Test scores range from 0-180 seconds with higher values indicating a worse outcome.

Secondary

MeasureTime frameDescription
Motor Evoked Potential Amplitude6 weeks post interventionMeasuring the amplitude of motor evoked potentials elicited by transcranial magnetic stimulation delivered over the motor cortex provides information about corticospinal excitability. Corticospinal excitability is a potential marker of MS disease burden that is responsive to physical training in people with MS and has been used to study experience-dependent neuroplasticity in other neurological conditions. The range of response amplitude is 0-100% of maximal muscle fibre recruitment, with higher values indicating better outcome.

Other

MeasureTime frameDescription
9-Hole Pegboard Test6 weeks post interventionThe 9-Hole Pegboard Test is a quantitative measure of upper extremity function. The test has a time limit of 300 seconds with higher values indicating a worse outcome.
Symbol Digit Modalities Test6 weeks post interventionThe Symbol Digit Modalities Test is used to asses divided attention, visual scanning, tracking and motor speed. The SDMT test is scored as the number of correct answers provided within 90 seconds (range: 0-110). A higher score would indicate a better outcome.
Peak Isometric Hand Grip Force6 weeks post interventionPeak Isometric Hand Grip Force provides a measure of general upper-extremity strength. Values typically range from 0 to approximately 75 kilograms of force, with higher values indicating greater strength.
Peak Isometric Knee Extensor Torque6 weeks post interventionPeak Isometric Knee Extensor Torque provides a measure of general lower-extremity strength. Values typically range from 0 to approximately 75 kg of force, with higher values indicating greater strength. Values typically range from 0 to approximately 300 Newton\*Meters of torque, with higher values indicating greater strength.
Mini Balance Evaluation Systems Test6 weeks post interventionThe Mini Balance Evaluation Systems Test provides an assessment of balance control systems. The Mini-BESTest has a high sensitivity in detecting balance impairments in people with MS. The Mini-BESTest has score values between 0-28 with a higher score meaning a better outcome.
Tumor Necrosis Factor Alpha concentration in systemic blood6 weeks post interventionTumor Necrosis Factor is an inflammatory cytokine that can be measured in human blood serum. Values typically range from 100 to 5000 picograms per milliliter of blood serum. Higher values are generally considered worse.
Brain-Derived Neurotrophic Factor in systemic blood6 weeks post interventionBrain-Derived Neurotrophic Factor is a neurotrophic growth factor that can be measured in human blood serum. Values typically range from 15 to 80 nanograms per milliliter of blood serum. Higher values are generally considered better.
Neurofilament Light concentration in systemic blood6 weeks post interventionNeurofilament Light is a neuronal cytoplasmic protein that can be measured in human blood serum. Values typically range from 0 to 100 picograms per milliliter of blood serum. Higher values are generally considered worse.
Peak Oxygen Uptake6 weeks post interventionPeak Oxygen Uptake provides a measure of cardiorespiratory fitness. It is measured through administration of a maximal exercise test. Values typically range from 0-90 milliliters per minute per kilogram.
Multiple Sclerosis Impact Scale6 weeks post interventionThe Multiple Sclerosis Impact Scale is a self-report survey that measures the impact of multiple sclerosis on physical and psychological functioning. The MSIS test has a score value between 0-145 with a higher score meaning a worse outcome.

Countries

Canada

Contacts

Primary ContactCameron Mang, PhD
cameron.mang@uregina.ca306-585-4066

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 7, 2026